Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of MCI-186 in Subjects With Renal Impairment
NCT03289208Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of edaravone in amyotrophic lateral sclerosis (ALS) and ischemic stroke (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started Oct 2016; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)ischemic stroke
Beyond the preview
Go deeper on NCT03289208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03289208.